Setiptiline

DB09304

small molecule experimental

Deskripsi

Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.

Struktur Molekul 2D

Berat 261.368
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

32 Data
Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Setiptiline.
Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Setiptiline.
Selegiline The risk or severity of adverse effects can be increased when Selegiline is combined with Setiptiline.
Moclobemide The risk or severity of adverse effects can be increased when Moclobemide is combined with Setiptiline.
Isocarboxazid The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Setiptiline.
Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Setiptiline.
Pargyline The risk or severity of adverse effects can be increased when Pargyline is combined with Setiptiline.
Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Setiptiline.
Iproniazid The risk or severity of adverse effects can be increased when Iproniazid is combined with Setiptiline.
Nialamide The risk or severity of adverse effects can be increased when Nialamide is combined with Setiptiline.
Pirlindole The risk or severity of adverse effects can be increased when Pirlindole is combined with Setiptiline.
Toloxatone The risk or severity of adverse effects can be increased when Toloxatone is combined with Setiptiline.
Hydracarbazine The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Setiptiline.
Methylene blue The risk or severity of adverse effects can be increased when Methylene blue is combined with Setiptiline.
Benmoxin The risk or severity of adverse effects can be increased when Benmoxin is combined with Setiptiline.
Mebanazine The risk or severity of adverse effects can be increased when Mebanazine is combined with Setiptiline.
Octamoxin The risk or severity of adverse effects can be increased when Octamoxin is combined with Setiptiline.
Pheniprazine The risk or severity of adverse effects can be increased when Pheniprazine is combined with Setiptiline.
Phenoxypropazine The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Setiptiline.
Pivhydrazine The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Setiptiline.
Safrazine The risk or severity of adverse effects can be increased when Safrazine is combined with Setiptiline.
Caroxazone The risk or severity of adverse effects can be increased when Caroxazone is combined with Setiptiline.
Furazolidone The risk or severity of adverse effects can be increased when Furazolidone is combined with Setiptiline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Setiptiline.
Harmaline The risk or severity of adverse effects can be increased when Harmaline is combined with Setiptiline.
Brofaromine The risk or severity of adverse effects can be increased when Brofaromine is combined with Setiptiline.
Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Setiptiline.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Setiptiline.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Setiptiline.
Safinamide The risk or severity of adverse effects can be increased when Safinamide is combined with Setiptiline.
Clorgiline The risk or severity of adverse effects can be increased when Clorgiline is combined with Setiptiline.
Levothyroxine The risk or severity of adverse effects can be increased when Levothyroxine is combined with Setiptiline.

Target Protein

Alpha-2 adrenergic receptors ADRA2A
Serotonin Receptors HTR1A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3792961
    Niho T, Ito C, Shibutani Y, Hashizume H, Yamaguchi K: Pharmacological properties of MO-8282, a novel antidepressant. Nihon Yakurigaku Zasshi. 1986 Oct;88(4):309-20.
  • PMID: 3774630
    Przegalinski E, Baran L, Siwanowicz J, Rawlow A: The lack of antidepressant properties and a potent central antiserotonin activity of Org 8282. Pol J Pharmacol Pharm. 1986 Jul-Aug;38(4):377-84.
  • PMID: 2806365
    Tohda M, Takasu T, Nomura Y: Effects of antidepressants on serotonin-evoked current in Xenopus oocytes injected with rat brain mRNA. Eur J Pharmacol. 1989 Jul 4;166(1):57-63.
  • PMID: -
    Kamimura M, Aoba A: Drug Therapy for Depression in Japan. JMAJ. 2002 Jan;45(1):28-33.
  • PMID: -
    Katsuda Y: Monoamine interaction —Effects of long-term treatments with L-tryptophan and setiptiline maleate on rat brain α2- and β-adrenergic receptor— Kawasaki Med J. 1991;17(1-4):37-45.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul